8-K Announcements
6Material company update
Mar 5, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Feb 12, 2026·SEC
Beam Therapeutics Inc.(BEAM)Earnings, Financials & Key Ratios
BEAM•NASDAQ
$32.33
$3.32B mkt cap·Price updated May 6, 2026
AboutBeam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.Show more
- Revenue$140M+120.0%
- EBITDA-$377M+4.1%
- Net Income-$80M+78.8%
- EPS (Diluted)-0.81+82.3%
- Gross Margin84.05%+117.6%
- EBITDA Margin-270.04%+56.4%
- Operating Margin-274.57%+58.0%
- Net Margin-57.24%+90.3%
- ROE-8.11%+81.5%
- ROIC-31.11%+33.6%
- Debt/Equity0.24+7.8%
- Interest Coverage-0.83
BEAM Key Insights
Beam Therapeutics Inc. (BEAM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 16.3%
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 466.3%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 20.2% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BEAM Price & Volume
Beam Therapeutics Inc. (BEAM) stock price & volume — 10-year historical chart
Loading chart...
BEAM Growth Metrics
Beam Therapeutics Inc. (BEAM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years466.27%
3 Years31.88%
TTM120.01%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM78.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM77.95%
Return on Capital
10 Years-42.74%
5 Years-32.71%
3 Years-28.78%
Last Year-33.28%
BEAM Recent Earnings
Beam Therapeutics Inc. (BEAM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (42%)
Q1 2026Latest
Feb 24, 2026EPS
$0.10
Est $1.13
+91.2%
Revenue
$114M
Est $12M
+877.9%
Q4 2025
Nov 4, 2025EPS
$1.10
Est $0.98
-12.2%
Revenue
$10M
Est $13M
-26.6%
Q3 2025
Aug 5, 2025EPS
$1.00
Est $1.04
+3.8%
Revenue
$8M
Est $12M
-26.6%
Q2 2025
May 6, 2025EPS
$1.24
Est $1.11
-11.7%
Revenue
$7M
Est $16M
-51.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $0.10vs $1.13+91.2% | $114Mvs $12M+877.9% |
| Q4 2025 | Nov 4, 2025 | $1.10vs $0.98-12.2% | $10Mvs $13M-26.6% |
| Q3 2025 | Aug 5, 2025 | $1.00vs $1.04+3.8% | $8Mvs $12M-26.6% |
| Q2 2025 | May 6, 2025 | $1.24vs $1.11-11.7% | $7Mvs $16M-51.9% |
Based on last 12 quarters of dataView full earnings history →
BEAM Peer Comparison
Beam Therapeutics Inc. (BEAM) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 PRME | 615.68M | 3.41 | -2.53 | 55.28% | -43.42% | -178.61% | 0.96 | |
 SGMO | 37.8M | 0.18 | -0.36 | -67.2% | -331.28% | -8.14% | 1.34 | |
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 |
Compare BEAM vs Peers
Beam Therapeutics Inc. (BEAM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BEAM Income Statement
Beam Therapeutics Inc. (BEAM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 18K | 24K | 51.84M | 60.92M | 377.71M | 63.52M | 139.74M |
| Revenue Growth % | - | - | - | 33.33% | 215916.67% | 17.51% | 520.01% | -83.18% | 120.01% |
| Cost of Goods Sold | 0 | 33.87M | 54.62M | 103.18M | 232.13M | 311.59M | 0 | 367.56M | 22.29M |
| COGS % of Revenue | - | - | 303438.89% | 429912.5% | 447.75% | 511.48% | - | 578.67% | 15.95% |
| Gross Profit | 0▲ 0% | -33.87M▲ 0% | -54.6M▼ 61.2% | -103.16M▼ 88.9% | -180.29M▼ 74.8% | -250.67M▼ 39.0% | 377.71M▲ 250.7% | -304.04M▼ 180.5% | 117.45M▲ 138.6% |
| Gross Margin % | - | - | -303338.89% | -429812.5% | -347.75% | -411.48% | 100% | -478.67% | 84.05% |
| Gross Profit Growth % | - | - | -61.19% | -88.93% | -74.78% | -39.04% | 250.68% | -180.5% | 138.63% |
| Operating Expenses | 8.6M | 11.87M | 20.55M | 29.6M | 212.18M | 87.81M | 554.19M | 111.53M | 501.14M |
| OpEx % of Revenue | - | - | 114183.33% | 123354.16% | 409.26% | 144.13% | 146.73% | 175.58% | 358.62% |
| Selling, General & Admin | 2.2M | 11.87M | 20.55M | 29.61M | 57.22M | 87.81M | 116.81M | 111.53M | 113.82M |
| SG&A % of Revenue | - | - | 114183.33% | 123354.17% | 110.37% | 144.13% | 30.93% | 175.58% | 81.45% |
| Research & Development | 5.86M | 33.87M | 54.62M | 103.18M | 387.09M | 311.59M | 437.38M | 367.56M | 409.62M |
| R&D % of Revenue | - | - | 303438.89% | 429912.5% | 746.64% | 511.48% | 115.8% | 578.67% | 293.12% |
| Other Operating Expenses | 0 | -33.87M | -54.62M | -103.18M | -232.13M | -311.59M | 0 | -367.56M | -22.29M |
| Operating Income | -8.6M▲ 0% | -45.74M▼ 432.1% | -75.15M▼ 64.3% | -132.76M▼ 76.7% | -392.46M▼ 195.6% | -338.48M▲ 13.8% | -176.49M▲ 47.9% | -415.57M▼ 135.5% | -383.69M▲ 7.7% |
| Operating Margin % | - | - | -417522.22% | -553166.66% | -757.01% | -555.61% | -46.73% | -654.25% | -274.57% |
| Operating Income Growth % | - | -432.1% | -64.3% | -76.65% | -195.62% | 13.76% | 47.86% | -135.47% | 7.67% |
| EBITDA | -8.58M | -45.09M | -71.65M | -128.03M | -385.01M | -324.33M | -146.95M | -393.64M | -377.36M |
| EBITDA Margin % | - | - | -398061.11% | -533437.5% | -742.64% | -532.39% | -38.91% | -619.73% | -270.04% |
| EBITDA Growth % | - | -425.27% | -58.9% | -78.68% | -200.73% | 15.76% | 54.69% | -167.87% | 4.14% |
| D&A (Non-Cash Add-back) | 12K | 650K | 3.5M | 4.73M | 7.45M | 14.15M | 29.53M | 21.93M | 6.34M |
| EBIT | -8.6M | -45.74M | -75.15M | -132.76M | -237.51M | -338.48M | -176.49M | -415.57M | -36.26M |
| Net Interest Income | 0 | 0 | 2.3M | 1.57M | 0 | 0 | 0 | 49.09M | -43.73M |
| Interest Income | 0 | 292K | 2.49M | 1.57M | 0 | 0 | 0 | 49.09M | 0 |
| Interest Expense | 0 | 0 | 187K | 0 | 0 | 0 | 0 | 0 | 43.73M |
| Other Income/Expense | -133.09K | -71M | -3.17M | -61.83M | 21.83M | 52.8M | 45.32M | 38.87M | 303.7M |
| Pretax Income | -8.73M▲ 0% | -116.74M▼ 1237.3% | -78.33M▲ 32.9% | -194.59M▼ 148.4% | -370.64M▼ 90.5% | -285.68M▲ 22.9% | -131.16M▲ 54.1% | -376.7M▼ 187.2% | -79.99M▲ 78.8% |
| Pretax Margin % | - | - | -435144.44% | -810800% | -714.91% | -468.94% | -34.73% | -593.07% | -57.24% |
| Income Tax | 500K | 0 | 0 | 0 | 0 | 3.41M | 1.37M | 39K | 0 |
| Effective Tax Rate % | -5.73% | 0% | 0% | 0% | 0% | -1.19% | -1.04% | -0.01% | 0% |
| Net Income | -8.73M▲ 0% | -115.26M▼ 1220.3% | -78.33M▲ 32.0% | -194.59M▼ 148.4% | -370.64M▼ 90.5% | -289.09M▲ 22.0% | -132.53M▲ 54.2% | -376.74M▼ 184.3% | -79.99M▲ 78.8% |
| Net Margin % | - | - | -435144.44% | -810800% | -714.91% | -474.54% | -35.09% | -593.13% | -57.24% |
| Net Income Growth % | - | -1220.32% | 32.04% | -148.44% | -90.47% | 22% | 54.16% | -184.28% | 78.77% |
| Net Income (Continuing) | -8.73M | -116.74M | -78.33M | -194.59M | -370.64M | -289.09M | -132.53M | -376.74M | -79.99M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.62▲ 0% | -3.28▼ 429.0% | -1.53▲ 53.4% | -5.49▼ 258.8% | -5.77▼ 5.1% | -4.13▲ 28.4% | -1.72▲ 58.4% | -4.58▼ 166.3% | -0.81▲ 82.3% |
| EPS Growth % | - | -429.03% | 53.35% | -258.82% | -5.1% | 28.42% | 58.35% | -166.28% | 82.31% |
| EPS (Basic) | -0.62 | -3.28 | -1.53 | -5.49 | -5.77 | -4.13 | -1.72 | -4.58 | -0.81 |
| Diluted Shares Outstanding | 12.95M | 35.14M | 51.34M | 46.73M | 64.23M | 70.02M | 77.15M | 82.31M | 98.91M |
| Basic Shares Outstanding | 12.95M | 35.14M | 51.34M | 46.73M | 64.23M | 70.02M | 77.15M | 82.31M | 98.91M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
BEAM Balance Sheet
Beam Therapeutics Inc. (BEAM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.04M | 148.28M | 94.54M | 308.32M | 1.27B | 1.09B | 1.21B | 878.15M | 1.27B |
| Cash & Short-Term Investments | 1.9M | 146.44M | 91.85M | 299.67M | 965.65M | 1.08B | 1.19B | 850.74M | 1.25B |
| Cash Only | 1.9M | 146.44M | 37.22M | 162.17M | 559.99M | 232.77M | 435.89M | 281.97M | 294.94M |
| Short-Term Investments | 0 | 0 | 54.63M | 137.5M | 405.65M | 845.37M | 753.98M | 568.77M | 950.27M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 300M | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | 2.11K | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 14.76M | 21.17M | 27.41M | 0 |
| Total Non-Current Assets | 365K | 18.74M | 61.55M | 143.36M | 201.45M | 248.82M | 248.67M | 225.68M | 212.49M |
| Property, Plant & Equipment | 335K | 16.94M | 43.25M | 125.37M | 186.98M | 234.13M | 237.81M | 216.28M | 205.18M |
| Fixed Asset Turnover | - | - | 0.00x | 0.00x | 0.28x | 0.26x | 1.59x | 0.29x | 0.68x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 30K | 1.49M | 0 | 0 | 0 | 0 | 0 | 0 | 6.68M |
| Other Non-Current Assets | 0 | 300K | 18.31M | 17.98M | 14.47M | 14.69M | 10.87M | 9.4M | 634K |
| Total Assets | 2.4M▲ 0% | 167.01M▲ 6853.0% | 156.1M▼ 6.5% | 451.68M▲ 189.4% | 1.47B▲ 226.4% | 1.34B▼ 9.0% | 1.46B▲ 8.8% | 1.1B▼ 24.4% | 1.48B▲ 34.2% |
| Asset Turnover | - | - | 0.00x | 0.00x | 0.04x | 0.05x | 0.26x | 0.06x | 0.09x |
| Asset Growth % | - | 6853.04% | -6.53% | 189.35% | 226.44% | -9% | 8.79% | -24.38% | 34.19% |
| Total Current Liabilities | 6.57M | 25.59M | 29.14M | 102.34M | 213.44M | 223.59M | 205.56M | 182.07M | 96.94M |
| Accounts Payable | 726K | 7.35M | 7.85M | 6.31M | 7.47M | 9.03M | 1.62M | 3.87M | 10.23M |
| Days Payables Outstanding | - | 79.21 | 52.43 | 22.34 | 11.75 | 10.58 | - | 3.84 | 167.5 |
| Short-Term Debt | 1.01M | 0 | 1.3M | 2.12M | 2.29M | 0 | 0 | 0 | 14.36M |
| Deferred Revenue (Current) | -1.01M | 0 | 0 | 24K | 86.27M | 135.97M | 68.71M | 108.86M | 6.66M |
| Other Current Liabilities | 4.7M | 16.54M | 12.56M | 83.02M | 60.83M | 49.68M | 100.69M | 19.74M | 36.34M |
| Current Ratio | 0.31x | 5.79x | 3.24x | 3.01x | 5.96x | 4.89x | 5.89x | 4.82x | 13.09x |
| Quick Ratio | 0.31x | 5.79x | 3.24x | 3.01x | 5.96x | 4.89x | 5.89x | 4.82x | 13.09x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 20K | 7.4M | 26.02M | 103.78M | 434.28M | 384.64M | 272.82M | 188.21M | 145.88M |
| Long-Term Debt | 0 | 0 | 4.41M | 5.29M | 3.01M | 0 | 0 | 0 | 139.76M |
| Capital Lease Obligations | 0 | 0 | 21.19M | 96.01M | 134.81M | 168.63M | 159.91M | 147.96M | 139.76M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 20K | 7.4M | 418K | 2.08M | 34.16M | 13.84M | 3.02M | 7.04M | -133.63M |
| Total Liabilities | 6.58M | 32.98M | 55.15M | 206.12M | 647.72M | 608.24M | 478.38M | 370.28M | 242.82M |
| Total Debt | 1.01M | 0 | 31.24M | 107.64M | 147.64M | 179M | 172.69M | 161.43M | 293.88M |
| Net Debt | -891K | -146.44M | -5.98M | -54.53M | -412.35M | -53.76M | -263.21M | -120.54M | -1.06M |
| Debt / Equity | - | - | 0.31x | 0.44x | 0.18x | 0.24x | 0.18x | 0.22x | 0.24x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -401.89x | - | - | - | - | - | -0.83x |
| Total Equity | -4.18M▲ 0% | 134.03M▲ 3304.1% | 100.94M▼ 24.7% | 245.56M▲ 143.3% | 826.74M▲ 236.7% | 733.47M▼ 11.3% | 981.33M▲ 33.8% | 733.54M▼ 25.2% | 1.24B▲ 68.8% |
| Equity Growth % | - | 3304.11% | -24.68% | 143.26% | 236.67% | -11.28% | 33.79% | -25.25% | 68.82% |
| Book Value per Share | -0.32 | 3.81 | 1.97 | 5.25 | 12.87 | 10.48 | 12.72 | 8.91 | 12.52 |
| Total Shareholders' Equity | -4.18M | 134.03M | 100.94M | 245.56M | 826.74M | 733.47M | 981.33M | 733.54M | 1.24B |
| Common Stock | 5K | 56K | 73K | 573K | 684K | 712K | 816K | 836K | 1.02M |
| Retained Earnings | -9.46M | -124.72M | -203.04M | -397.64M | -768.27M | -1.06B | -1.19B | -1.57B | -1.64B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -11K | -661K | 16K | -9K | -50K | -2.43M | 604K | 679K | 1.11M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BEAM Cash Flow Statement
Beam Therapeutics Inc. (BEAM) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.71M | -20.3M | -72M | -95.74M | -66.27M | 22.53M | -149.19M | -347.25M | -345.1M |
| Operating CF Margin % | - | - | -400016.67% | -398920.83% | -127.82% | 36.98% | -39.5% | -546.69% | -246.95% |
| Operating CF Growth % | - | -649.83% | -254.73% | -32.97% | 30.78% | 133.99% | -762.29% | -132.75% | 0.62% |
| Net Income | -8M | -116.74M | -78.33M | -194.59M | -370.64M | -289.09M | -132.53M | -376.74M | -79.99M |
| Depreciation & Amortization | 11K | 650K | 3.5M | 4.74M | 7.45M | 14.15M | 20.01M | 21.93M | 22.29M |
| Stock-Based Compensation | 198K | 7M | 7.03M | 15.38M | 43.57M | 84.32M | 98.65M | 120.66M | 94.24M |
| Deferred Taxes | 500K | 11.75M | 0 | 63.52M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.85M | 66.96M | 6.5M | 9.87M | 142.09M | -38.48M | -18.87M | -2.87M | -250.63M |
| Working Capital Changes | 740K | 10.07M | -10.71M | 5.35M | 111.25M | 251.63M | -116.45M | -110.22M | -131.02M |
| Change in Receivables | 0 | 0 | 0 | 0 | -300M | 300M | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -300M | 0 | 0 | 0 |
| Change in Payables | 726K | 2.44M | 4.09M | 60K | 818K | 2.37M | -7.58M | 1.81M | 6.04M |
| Cash from Investing | -346K | -13.42M | -66.66M | -100.12M | -294.14M | -461.34M | 71.84M | 185.01M | -121.44M |
| Capital Expenditures | -346K | -13.12M | -12.52M | -16.36M | -46.81M | -48.95M | -33.73M | -8.95M | -14.95M |
| CapEx % of Revenue | - | - | 69544.44% | 68154.17% | 90.29% | 80.35% | 8.93% | 14.08% | 10.7% |
| Acquisitions | 0 | 0 | 0 | 83.77M | 620K | 412.38M | 0 | 0 | -78K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -300K | 0 | -83.77M | 0 | -412.38M | 0 | 0 | 254.75M |
| Cash from Financing | 4.98M | 179.73M | 41.28M | 322.32M | 756.14M | 111.59M | 276.45M | 7.74M | 478.05M |
| Debt Issued (Net) | 0 | 0 | 5.71M | 1.7M | -2.12M | -2.29M | -2.25M | -485K | 0 |
| Equity Issued (Net) | 4.98M | 179.72M | 37.9M | 319.53M | 757.45M | 108.26M | 270.17M | 8.22M | 478.05M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 10K | -2.34M | 1.1M | 810K | 5.62M | 8.53M | 0 | 0 |
| Net Change in Cash | 1.93M▲ 0% | 146M▲ 7461.1% | -97.38M▼ 166.7% | 126.46M▲ 229.9% | 395.73M▲ 212.9% | -327.22M▼ 182.7% | 199.09M▲ 160.8% | -154.5M▼ 177.6% | 11.51M▲ 107.4% |
| Free Cash Flow | -3.05M▲ 0% | -33.42M▼ 994.7% | -84.52M▼ 152.9% | -112.1M▼ 32.6% | -113.08M▼ 0.9% | -26.42M▲ 76.6% | -182.93M▼ 592.3% | -356.19M▼ 94.7% | -360.05M▼ 1.1% |
| FCF Margin % | - | - | -469561.11% | -467075% | -218.11% | -43.37% | -48.43% | -560.77% | -257.65% |
| FCF Growth % | - | -994.73% | -152.89% | -32.63% | -0.88% | 76.63% | -592.28% | -94.72% | -1.08% |
| FCF per Share | -0.24 | -0.95 | -1.65 | -2.40 | -1.76 | -0.38 | -2.37 | -4.33 | -3.64 |
| FCF Conversion (FCF/Net Income) | 0.31x | 0.18x | 0.92x | 0.49x | 0.18x | -0.08x | 1.13x | 0.92x | 4.31x |
| Interest Paid | 0 | 0 | 187K | 0 | 567K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BEAM Key Ratios
Beam Therapeutics Inc. (BEAM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -177.53% | -66.67% | -112.32% | -69.13% | -37.06% | -15.46% | -43.94% | -8.11% |
| Return on Invested Capital (ROIC) | - | - | -136.57% | -69.63% | -97.24% | -46.41% | -18.94% | -46.83% | -31.11% |
| Gross Margin | - | - | -303338.89% | -429812.5% | -347.75% | -411.48% | 100% | -478.67% | 84.05% |
| Net Margin | - | - | -435144.44% | -810800% | -714.91% | -474.54% | -35.09% | -593.13% | -57.24% |
| Debt / Equity | - | - | 0.31x | 0.44x | 0.18x | 0.24x | 0.18x | 0.22x | 0.24x |
| Interest Coverage | - | - | -401.89x | - | - | - | - | - | -0.83x |
| FCF Conversion | 0.31x | 0.18x | 0.92x | 0.49x | 0.18x | -0.08x | 1.13x | 0.92x | 4.31x |
| Revenue Growth | - | - | - | 33.33% | 215916.67% | 17.51% | 520.01% | -83.18% | 120.01% |
BEAM SEC Filings & Documents
Beam Therapeutics Inc. (BEAM) SEC filings — annual & quarterly reports (10-K, 10-Q)
BEAM Frequently Asked Questions
Beam Therapeutics Inc. (BEAM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Beam Therapeutics Inc. (BEAM) reported $139.7M in revenue for fiscal year 2025.
Beam Therapeutics Inc. (BEAM) grew revenue by 120.0% over the past year. This is strong growth.
Beam Therapeutics Inc. (BEAM) reported a net loss of $80.0M for fiscal year 2025.
Dividend & Returns
Beam Therapeutics Inc. (BEAM) has a return on equity (ROE) of -8.1%. Negative ROE indicates the company is unprofitable.
Beam Therapeutics Inc. (BEAM) had negative free cash flow of $360.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More BEAM
Beam Therapeutics Inc. (BEAM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates